In the BioHarmony Drug Report Database

"Preview" Icon

Trifarotene

Aklief (trifarotene) is a small molecule pharmaceutical. Trifarotene was first approved as Aklief on 2019-10-04. It is used to treat acne vulgaris in the USA. The pharmaceutical is active against retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor beta and retinoic acid receptor alpha. Aklief’s patents are valid until 2033-05-30 (FDA).

 

Trade Name

 

Aklief
 

Common Name

 

trifarotene
 

ChEMBL ID

 

CHEMBL3707313
 

Indication

 

acne vulgaris
 

Drug Class

 

Arotinoid derivatives

Image (chem structure or protein)

Trifarotene structure rendering